Nicotine replacement combined with a novel compound (ProBAN) for smoking cessation: a pilot study.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Of 107 subjects seen at the screening visit, 27 were excluded because of comorbid illness or concomitant medication use.

Who Took Part

According to the abstract, 107 subjects were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Healthy adult smokers were recruited via advertisements.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the subjects nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

Some subjects received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

A 12-week, prospective, double-blind, randomized, placebo controlled pilot study.

The primary outcome was complete continuous abstinence of smoking from one through 12 weeks after the quit date.

What Was Measured

PubMed files the paper under topics including Administration, Sublingual, Chewing Gum, Cholinesterase Reactivators, Drug Combinations, Ipratropium, Nicotine and Pilot Projects.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 107 subjects.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Canadian respiratory journal), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.